MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Linagliptin

CAS No. : 668270-12-0

MCE 国际站：Linagliptin

产品活性：Linagliptin 是一种有效，选择性的 DPP-4 抑制剂，IC₅₀ 值为 1 nM。

研究领域：Metabolic Enzyme/Protease  |  Autophagy  |  Apoptosis

作用靶点：Dipeptidyl Peptidase  |  Autophagy  |  Ferroptosis

In Vitro: Linagliptin inhibits DPP-4 activity in vitro in several independent experiments with IC₅₀ values of 0.4, 0.5, 0.9, and 1.1 nM (mean IC₅₀, approximately 1 nM). Linagliptin inhibits FAP with an IC₅₀ of 89 nM (approximately 90-fold selectivity versus DPP-4).

In Vivo: In male Wistar rats, Beagle dogs, and Rhesus monkeys, xanthine linagliptin proves to be a highly efficacious, long-lasting, and potent DPP-4 inhibitor providing >70% inhibition for >7 h for all three species after oral administration of 1 mg/kg. Single oral administration of linagliptin to db/db mice 45 min prior to an oral glucose tolerance test reduced plasma glucose excursion in a dose-dependent manner from 0.1 mg/kg (15% inhibition) to 1 mg/kg (66% inhibition). Linagliptin (3 and 10 mg/kg) dose-dependently inhibits the DPP-4 enzyme in plasma within 30 min of administration. Linagliptin (1 mg/kg, p.o.) significantly reduces glucose excursion by approximately 50%. Oral administration of the DPP-4 inhibitor linagliptin (3 mg/kg, p.o.) strongly reduces DPP-4 activity, stabilizes active GLP-1 in chronic wounds, and improves healing in ob/ob mice. At day 10 postwounding, linagliptin-treated ob/ob mice show largely epithelialized wounds characterized by the absence of neutrophils.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Antiviral Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Anti-diabetic Compound Library  |  Ferroptosis Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Children’s Drug Library  |  EMA-Approved Drug Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  Highly Selective Activators Library  |  Sorafenib-d₄  |  Lapatinib ditosylate  |  Ciclopirox olamine  |  Curcumin  |  L-Glutamine-d₅  |  HDAC-IN-48  |  NVP-DPP728  |  Gemigliptin  |  (S)-L-Cystine-¹⁵N₂  |  L-Glutamine-¹³C₅,¹⁵N₂  |  Lapatinib-d₇ dihydrochloride  |  Sorafenib Tosylate  |  Deferiprone  |  Cycloheximide  |  Pravastatin sodium  |  YL-939  |  (-)-Epicatechin  |  Dopamine-d₅ hydrochloride  |  DPP IV/hCA II-IN-1  |  Linagliptin-d₄  |  HAEGT  |  Ellipyrone A  |  2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one  |  Acetylcysteine-d₃  |  Dopamine hydrochloride  |  (E)-Ferulic acid  |  Anagliptin hydrochloride  |  PD146176  |  Pifithrin-β hydrobromide

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。